Targeted 5-HT_1F Therapies for Migraine

Area of Science:

• Neurology
• Pharmacology

Background:

• Migraine is a prevalent and disabling neurological disorder.
• Current treatments, such as triptans, have limitations including cardiovascular risks.
• There is a need for novel migraine therapies with improved safety profiles.

Purpose of the Study:

• To review the development and therapeutic potential of 5-HT1 receptor agonists for migraine treatment.
• To evaluate lasmiditan, a selective 5-HT1F receptor agonist, as a novel antimigraine agent.
• To discuss the safety and efficacy of lasmiditan, particularly its lack of cardiovascular effects.

Main Methods:

• Review of preclinical studies on lasmiditan's receptor affinity and vasoconstrictive effects.
• Analysis of clinical trial data regarding lasmiditan's safety and tolerability.
• Examination of lasmiditan's mechanism of action, including blood-brain barrier penetration and receptor interaction.

Main Results:

• Lasmiditan exhibits high affinity for the 5-HT1F receptor and minimal affinity for the vasoconstrictive 5-HT1B receptor.
• Preclinical and clinical data suggest lasmiditan does not cause vasoconstriction or cardiac events.
• Lasmiditan is well-tolerated and crosses the blood-brain barrier to act on trigeminal neurons.

Conclusions:

• Selective 5-HT1F receptor agonists, like lasmiditan, represent a promising advancement in migraine therapy.
• Lasmiditan may offer an effective and safer alternative for acute migraine treatment, especially for patients with cardiovascular concerns.
• Further phase III trials are necessary to confirm the long-term efficacy and safety of lasmiditan.